 Cybin Inc. NYSE:CYBN a company developing novel psychedelic compounds for therapeutic use, has received a Schedule I manufacturing license from the U.S. Drug Enforcement Agency DEA. The DEA license is a federal requirement for any investigators intending to study, produce or analyze Schedule I substances. 